Publications Archives - Page 2 of 3 - Alzheon | Preserving Future Memories

2 Dec, 2019

APOE4/4 Subjects with Early Alzheimer’s Disease Show Accelerated Loss of Cortical Thickness and Cognitive Decline Compared to APOE3/3 Subjects

alzheon2019-11-27T16:57:28-05:00December 2nd, 2019|

24 Oct, 2018

APOE4/4 Early to Mild AD Subjects Show High Rates of Hippocampal Atrophy and Cognitive Decline in ADNI-1 and Tramiprosate Datasets

alzheon2019-09-23T12:10:47-04:00October 24th, 2018|

24 Oct, 2018

Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses of Cognitive and Functional Outcomes

alzheon2019-09-23T12:10:47-04:00October 24th, 2018|

3 Aug, 2018

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation In Human Brain

alzheon2024-06-19T16:49:25-04:00August 3rd, 2018|

25 Jul, 2018

Clinical Benefits of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses from the Phase 3 North American Trial

alzheon2019-09-23T12:10:47-04:00July 25th, 2018|

2 Nov, 2017

Sustained Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Alzheimer’s Disease Over 130 Weeks: Results of Phase 3 Extension Study

alzheon2019-09-23T12:10:48-04:00November 2nd, 2017|

23 Oct, 2017

Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease

alzheon2019-09-23T12:10:48-04:00October 23rd, 2017|

17 Jul, 2017

ALZ-801 Mechanism of Action: Stoichiometry of Beta Amyloid Anti-Oligomer Effect, PK/PD, and Clinical Dose Selection for Confirmatory Phase 3 Program in Alzheimer’s Disease

alzheon2019-09-23T12:10:49-04:00July 17th, 2017|

22 Jun, 2017

Clinical Effects Of Tramiprosate In APOE4/4 Homozygous Patients With Mild Alzheimer’s Disease Suggest Disease Modification Potential

alzheon2019-09-23T12:10:49-04:00June 22nd, 2017|

24 Apr, 2017

Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data

alzheon2019-09-23T12:10:49-04:00April 24th, 2017|